DDB1- and CUL4-associated factor 15
1_MAPSS 6_ KSERN 11_ SGAGS 16_ GGGGP 21_ GGAGG 26_ KRAAG 31_ RRREH 36_ VLKQL 41_ ERVKI 46_ SGQLS 51_ PRLFR 56_ KLPPR 61_ VCVSL 66_ KNIVD 71_ EDFLY 76_ AGHIF 81_ LGFSK 86_ CGRYV 91_ LSYTS 96_ SSGDD 101_ DFSFY 106_ IYHLY 111_ WWEFN 116_ VHSKL 121_ KLVRQ 126_ VRLFQ 131_ DEEIY 136_ SDLYL 141_ TVCEW 146_ PSDAS 151_ KVIVF 156_ GFNTR 161_ SANGM 166_ LMNMM 171_ MMSDE 176_ NHRDI 181_ YVSTV 186_ AVPPP 191_ GRCAA 196_ CQDAS 201_ RAHPG 206_ DPNAQ 211_ CLRHG 216_ FMLHT 221_ KYQVV 226_ YPFPT 231_ FQPAF 236_ QLKKD 241_ QVVLL 246_ NTSYS 251_ LVACA 256_ VSVHS 261_ AGDRS 266_ FCQIL 271_ YDHST 276_ CPLAP 281_ ASPPE 286_ PQSPE 291_ LPPAL 296_ PSFCP 301_ EAAPA 306_ RSSGS 311_ PEPSP 316_ AIAKA 321_ KEFVA 326_ DIFRR 331_ AKEAK 336_ GGVPE 341_ EARPA 346_ LCPGP 351_ SGSRC 356_ RAHSE 361_ PLALC 366_ GETAP 371_ RDSPP 376_ ASEAP 381_ ASEPG 386_ YVNYT 391_ KLYYV 396_ LESGE 401_ GTEPE 406_ DELED 411_ DKISL 416_ PFVVT 421_ DLRGR 426_ NLRPM 431_ RERTA 436_ VQGQY 441_ LTVEQ 446_ LTLDF 451_ EYVIN 456_ EVIRH 461_ DATWG 466_ HQFCS 471_ FSDYD 476_ IVILE 481_ VCPET 486_ NQVLI 491_ NIGLL 496_ LLAFP 501_ SPTEE 506_ GQLRP 511_ KTYHT 516_ SLKVA 521_ WDLNT 526_ GIFET 531_ VSVGD 536_ LTEVK 541_ GQTSG 546_ SVWSS 551_ YRKSC 556_ VDMVM 561_ KWLVP 566_ ESSGR 571_ YVNRM 576_ TNEAL 581_ HKGCS 586_ LKVLA 591_DSERY
1: Substrate-recognition component of the DCX(DCAF15) complex, a cullin-4-RING E3 ubiquitin-protein ligase complex that mediates ubiquitination and degradation of target proteins (PubMed:16949367, PubMed:31452512). The DCX(DCAF15) complex acts as a regulator of the natural killer (NK) cells effector functions, possibly by mediating ubiquitination and degradation of cohesin subunits SMC1A and SMC3 (PubMed:31452512). May play a role in the activation of antigen-presenting cells (APC) and their interaction with NK cells (PubMed:31452512)
2: Binding of aryl sulfonamide anticancer drugs, such as indisulam (E7070) or E7820, change the substrate specificity of the DCX(DCAF15) complex, leading to promote ubiquitination and degradation of splicing factor RBM39 (PubMed:28302793, PubMed:28437394, PubMed:31452512, PubMed:31693891). RBM39 degradation results in splicing defects and death in cancer cell lines (PubMed:28302793, PubMed:28437394, PubMed:31693891). Aryl sulfonamide anticancer drugs change the substrate specificity of DCAF15 by acting as a molecular glue that promotes binding between DCAF15 and weak affinity interactor RBM39 (PubMed:31686031, PubMed:31819272). Aryl sulfonamide anticancer drugs also promote ubiquitination and degradation of RBM23 and PRPF39 (PubMed:31626998, PubMed:31686031, PubMed:31693891)